| Quick Answer |
| In type 2 diabetes, the GLP-1 receptor agonists and the newer dual GIP and GLP-1 medicines lead to the largest weight loss, according to the American Diabetes Association’s 2026 Standards of Care. SGLT2 tablets help modestly, the long-standing first-line tablet is close to weight neutral, and insulin and sulfonylureas tend to add weight. The right choice is a decision you make with your doctor. |
Why does weight matter so much once you have diabetes?
Ask most people with type 2 diabetes what their doctor tracks and they will say sugar. Fasting readings, HbA1c, the number that jumps after a Sunday plate of biryani.
Weight usually sits lower on that list, something to “work on” once the sugar settles. Diabetes specialists have spent the last few years arguing that the order should flip.
A 2022 review in The Lancet, Obesity management as a primary treatment goal for type 2 diabetes, made the case plainly: losing weight can reverse some of the metabolic faults that drive diabetes, and it improves sugar control in a way that sugar-lowering treatment alone cannot match. The ADA Standards of Care in Diabetes 2026 treat weight management as a separate treatment goal that sits beside glucose control.
For India this is a practical question, not an academic one.
The national ICMR-INDIAB study estimated that 11.4% of Indian adults (about 101 million people) live with diabetes. The same survey found generalised obesity in 28.6% of adults and abdominal obesity in 39.5%. Those groups overlap heavily, which is why so many people walk into a diabetologist’s clinic with one hope: if I need medicine anyway, can it help my weight too?
Which diabetes medicines actually move the scale?
Some move it a lot, some barely, and a few push it the wrong way. The ADA 2026 Standards grade every major diabetes medicine family on its weight effect, and that grading is the cleanest summary available.
| Medicine family | How it is taken | Weight effect (ADA 2026 grading) |
| Dual GIP and GLP-1 receptor agonists | Weekly injection | Loss, very high |
| GLP-1 receptor agonists | Weekly or daily injection; one is also made as a daily tablet | Loss, intermediate to very high depending on the medicine |
| SGLT2 inhibitors (the gliflozins) | Daily tablet | Loss, intermediate |
| Biguanide (the long-standing first-line tablet) | Daily tablet | Neutral, with potential for modest loss |
| DPP-4 inhibitors (the gliptins) | Daily tablet | Neutral |
| Glitazones | Daily tablet | Gain |
| Sulfonylureas | Daily tablet | Gain |
| Insulin | Injection | Gain |
Source: Table 9.2, ADA Standards of Care in Diabetes 2026, Section 9.
GLP-1 medicines and the dual GIP and GLP-1 medicines
GLP-1 is a hormone your gut releases after a meal. It nudges the pancreas to release insulin when sugar is high, slows the stomach slightly, and quiets the hunger signals reaching the brain.
Medicines built on this hormone were designed to lower blood sugar. People taking them also ate less, and the weight effect turned out to be substantial enough to reshape how diabetes is treated.
The dual medicines add a second gut hormone, GIP, to the same approach. In the SURPASS-2 trial, published in the New England Journal of Medicine, a dual medicine was tested head to head against a GLP-1 medicine in adults with type 2 diabetes. It brought down both HbA1c and body weight more at every dose studied.
The ADA’s own position follows from this. For people with type 2 diabetes and obesity, it advises that glucose-lowering medicines which promote weight loss should be prioritised, and it places these two families at the top of its weight grading.
SGLT2 tablets
These tablets make the kidneys pass extra sugar out in urine, and some calories leave with it. The weight effect is real but moderate.
Their stronger case is protection. The ADA recommends them for people with diabetes and heart failure, and alongside GLP-1 medicines for chronic kidney disease, whatever the HbA1c. A doctor may choose one for your heart or kidneys first and count the weight effect as a bonus.
The first-line tablet many people start on
The biguanide tablet that is often the first prescription after a diagnosis is close to weight neutral, with the ADA noting a potential for modest loss. It is safe, well studied and good at its actual job, which is sugar. It simply is not a weight medicine, and expecting it to behave like one leads to disappointment.
The ones that can add kilos
Insulin, sulfonylureas and glitazones all lower sugar well, and the ADA lists all of them as causing weight gain. Its advice for people living with obesity is to use them judiciously and at the lowest dose that works.
If you have been on one of these for years and your trousers have been quietly getting tighter, that is worth raising at your next review. It is not a reason to stop anything on your own.
Do these medicines work as well when you already have diabetes?
On average, a little less. Two large trials tested this directly.
The STEP 2 trial (The Lancet, 2021) gave a weekly GLP-1 medicine to adults with type 2 diabetes and overweight or obesity. It compared a higher weight-management dose against the lower dose used for diabetes, and against placebo. The higher dose produced clearly more weight loss than either.
The SURMOUNT-2 trial (The Lancet, 2023) did the same for a dual GIP and GLP-1 medicine in adults with obesity and type 2 diabetes. Weight fell substantially, and HbA1c improved alongside it.
Set those results beside SURMOUNT-1, a trial of the same medicine in adults with obesity but without diabetes. There, some participants lost up to 20% of their body weight. The SURMOUNT-2 authors point out that people living with both obesity and type 2 diabetes have tended to lose less weight on obesity medicines than people without diabetes, and their own results followed that pattern.
Two lessons come out of this. A lower average is still a meaningful result for blood sugar. And dose matters: a diabetes dose and a weight-management dose of the same medicine are different prescriptions, which STEP 2 showed plainly.
Why should Indian adults read these trials a little differently?
Look at who took part. SURMOUNT-2 enrolled adults with a BMI of 27 or more, and roughly three quarters of participants were White. Few of them resembled a 48-year-old accountant in Pune with a BMI of 25 and a waist that has crept past 90 cm.
That gap matters because Indian bodies carry metabolic risk at lower weights.
Indian guidance has long treated a BMI of 23 as overweight and 25 as obesity, against the 25 and 30 used on Western charts. The 2025 revised definition of obesity in Asian Indians (Misra and colleagues, Diabetes & Metabolic Syndrome: Clinical Research & Reviews) goes further. It begins obesity staging at a BMI above 23 and puts the belly at the centre of the diagnosis, using a waist of 90 cm or more in men and 80 cm or more in women, or a waist-to-height ratio above 0.5.
The same paper notes that Asian Indians carry more body fat for any given BMI, and that this abdominal fat is closely tied to insulin resistance. So a person who looks only “a little heavy” by Western standards can be metabolically closer to a trial participant than their BMI suggests.
Our view: that is a good reason to discuss weight-focused diabetes treatment earlier with your doctor. It is never a reason to source a prescription medicine yourself.
What should you watch for day to day?
With GLP-1 and dual medicines, the common complaints are nausea, early fullness and, for some, vomiting or loose stools. In STEP 2 these were mostly mild to moderate and showed up while the dose was being stepped up.
The ADA suggests smaller meals, stopping once you feel full, and easing off high-fat or spicy food during this phase. A rainy evening with a plate of pakoras is usually where people discover this advice for themselves.
These medicines are not recommended for people with gastroparesis, and the ADA asks doctors to watch for gallbladder problems and to stop treatment if pancreatitis is suspected. Tell your surgeon or anaesthetist you are on one before any procedure that needs sedation.
SGLT2 tablets bring a different concern. The ADA advises pausing them during prolonged fasting or serious illness because of a rare but dangerous form of ketoacidosis. If you keep long religious fasts, during Ramzan or Navratri for example, plan your medicines with your doctor beforehand.
One more trap: adding a GLP-1 medicine on top of insulin or a sulfonylurea can push sugar too low. The ADA tells doctors to reassess those doses when a new medicine starts, which is one more reason none of this should be adjusted at home.
How do doctors decide which medicine fits you?
There is no single winner for everyone. The ADA calls for shared decision-making that weighs heart, kidney and liver health, weight goals, the risk of low sugar, side effects, access and personal preference.
In practice your doctor will look at your HbA1c, kidney function, heart history, other medicines, any history of pancreatitis or thyroid problems, and your BMI and waist against Indian thresholds. Then comes the slow part: starting low, stepping the dose up, and checking in regularly.
GLP-1 and dual medicines are prescription-only in India. They are meant to sit inside a supervised plan that also looks at food, movement, sleep and muscle, and they need a doctor watching the whole picture.
| Conclusion |
| Among diabetes medicines, the dual GIP and GLP-1 medicines and the GLP-1 medicines have the strongest weight effect, SGLT2 tablets help modestly, and insulin, sulfonylureas and glitazones can add weight. People with diabetes tend to lose a little less on these medicines than people without it, and Indian bodies carry risk at lower BMI and waist sizes than the trials reflect. The right medicine depends on your heart, kidneys, sugar and weight together, and that decision belongs with your doctor. |
Frequently asked questions
1. Are these the same medicines prescribed for weight loss in people without diabetes?
They belong to the same families, but the dose is often different. The STEP 2 trial compared a diabetes dose with a higher weight-management dose of the same GLP-1 medicine, and the higher dose led to more weight loss. Your doctor decides which dose and indication fit you.
2. Will the diabetes tablet I already take help me lose weight?
It depends on the tablet. The ADA grades the first-line biguanide as close to weight neutral, SGLT2 tablets as giving modest loss, gliptins as neutral, and sulfonylureas and glitazones as causing gain. Ask your doctor which group yours falls in before drawing conclusions.
3. Do I need a BMI of 30 for a doctor to consider weight-focused treatment?
Not in India. Indian guidance treats a BMI of 25 as obesity, and the 2025 revised definition starts obesity staging above 23, with a waist of 90 cm in men or 80 cm in women as a key marker. Whether a medicine suits you is still a clinical judgement made after a full assessment.
4. What happens to my weight if I stop the medicine?
Weight tends to come back. In the SURMOUNT-4 trial (JAMA, 2024), adults without diabetes who were switched from a dual GIP and GLP-1 medicine to placebo regained a large part of the weight they had lost, while those who continued kept losing. Any change to your treatment should be planned with your doctor.
5. Can I keep a religious fast while on these medicines?
Talk to your doctor before the fast, not during it. The ADA advises pausing SGLT2 tablets during prolonged fasting, and fasting while on insulin or sulfonylureas raises the risk of low sugar. Your doctor can adjust doses for Ramzan, Navratri or Ekadashi so you can fast more safely.
| Medical Disclaimer |
| This article is for general education and is not a substitute for medical advice, diagnosis or treatment. The medicines discussed here are prescription-only in India and must be used only under the supervision of a qualified doctor. Do not start, stop or change any diabetes or weight medicine without speaking to your doctor. Individual results vary. |
